Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R21 with AS01B in healthy volunteers
NCT02600975Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Dec 2015
- Primary completion
- Jan 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of R21/Matrix-M in malaria, sponsored by University of Oxford. Primary endpoint: Safety and tolerability of R21 with AS01B at 34 weeks. Started Dec 2015; status: completed.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02600975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02600975.